Cargando…
A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control
BACKGROUND: The enhanced thrombotic milieu in diabetes contributes to increased risk of vascular events. Aspirin, a key antiplatelet agent, has inconsistent effects on outcomes in diabetes and the best dosing regimen remains unclear. This work investigated effects of aspirin dose and interaction wit...
Autores principales: | Parker, William A. E., Sagar, Rebecca, Kurdee, Zeyad, Hawkins, Fladia, Naseem, Khalid M., Grant, Peter J., Storey, Robert F., Ajjan, Ramzi A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684134/ https://www.ncbi.nlm.nih.gov/pubmed/34920734 http://dx.doi.org/10.1186/s12933-021-01427-y |
Ejemplares similares
-
Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels
por: Parker, William A. E., et al.
Publicado: (2020) -
Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial
por: O’Mahoney, Lauren L., et al.
Publicado: (2020) -
Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes
por: Swoboda, Peter P., et al.
Publicado: (2018) -
Non-Traditional Pathways for Platelet Pathophysiology in Diabetes: Implications for Future Therapeutic Targets
por: Sagar, Rebecca C., et al.
Publicado: (2022) -
Antithrombotic therapy in diabetes: which, when, and for how long?
por: Ajjan, Ramzi A, et al.
Publicado: (2021)